Table 3.
The subgroup analysis of the correlation of GH with clinical outcomes.
| Subgroup | Study (n) | Case (n) | SMD/MD 95% CI | p | I2 (%) | Model |
|---|---|---|---|---|---|---|
| Number of oocytes retrieved | ||||||
| GH dose ≥ 4.5 IU/d | 4 | 368 | 1.38 [0.88, 1.87] | <0.00001 | 61 | Random |
| GH dose < 4.5 IU/d | 3 | 218 | 0.67 [0.18, 1.15] | 0.008 | 85 | Random |
| GnRH antagonist protocol | 6 | 481 | 1.09 [0.59, 1.58] | <0.0001 | 90 | Random |
| GnRH agonist protocol | 2 | 225 | 0.36 [-0.25, 0.96] | 0.25 | 65 | Random |
| Number of optimal embryos | ||||||
| GH dose ≥ 4.5 IU/d | 2 | 205 | 0.31 [0.01, 0.62] | 0.04 | 73 | Random |
| GH dose < 4.5 IU/d | 2 | 170 | 0.25 [-0.11, 0.61] | 0.17 | 96 | Random |
| E2 on the day of hCG | ||||||
| GH dose ≥ 4.5 IU/d | 4 | 368 | 1.25 [0.35, 2.15] | 0.007 | 94 | Random |
| GH dose < 4.5 IU/d | 3 | 234 | 1.10 [-0.34, 2.54] | 0.14 | 96 | Random |